Stock Traders Purchase Large Volume of Call Options on Solventum (NYSE:SOLV)

Solventum Corporation (NYSE:SOLV) was the target of some unusual options trading activity on Tuesday. Stock traders bought 3,171 call options on the stock. This is an increase of approximately 1,153% compared to the average daily volume of 253 call options.

Solventum Trading Down 2.0%

Shares of NYSE:SOLV traded down $1.81 during trading on Thursday, reaching $86.74. The company’s stock had a trading volume of 393,719 shares, compared to its average volume of 1,407,073. The stock has a market capitalization of $15.02 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 1.33 and a beta of 0.66. Solventum has a 12 month low of $62.38 and a 12 month high of $88.65. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The firm’s 50 day simple moving average is $78.03 and its two-hundred day simple moving average is $74.19.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts predict that Solventum will post 6.58 EPS for the current fiscal year.

Analyst Ratings Changes

SOLV has been the topic of several research reports. BTIG Research reaffirmed a “buy” rating and issued a $91.00 target price on shares of Solventum in a report on Monday, July 13th. Wedbush began coverage on Solventum in a report on Friday, May 15th. They set an “outperform” rating and a $94.00 price target for the company. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. KeyCorp upped their price objective on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, BMO Capital Markets initiated coverage on Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 target price for the company. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $86.00.

Hedge Funds Weigh In On Solventum

Several large investors have recently modified their holdings of SOLV. Independent Franchise Partners LLP boosted its stake in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the period. Norges Bank bought a new stake in Solventum in the fourth quarter worth about $147,467,000. Diamond Hill Capital Management Inc. boosted its position in shares of Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares during the period. Boston Partners grew its stake in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Solventum by 20.0% during the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.